Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s12098-009-0093-2 | DOI Listing |
J Dr Nurs Pract
January 2025
Department of Nursing, Miami University, Oxford, OH, USA
Over 30% of births in the United States occur via cesarean section despite increased risks to the birthing person and neonate. Evidence-based nursing practice related to fetal monitoring, patient positioning, and management of the second stage of labor can decrease the incidence of cesarean birth. The objective is to decrease the cesarean birth rate by 3% in a Midwestern suburban hospital.
View Article and Find Full Text PDFBackground: Neonatal mice are frequently used to model diseases that affect human infants. Microbial community composition has been shown to impact disease progression in these models. Despite this, the maturation of the early-life murine microbiome has not been well-characterized.
View Article and Find Full Text PDFNutr Clin Pract
January 2025
Department of Nutrition, Centre Hospitalier Universitaire Sainte-Justine Research Center, Université de Montréal, Montréal, Québec, Canada.
Background: When exposed to ambient light, parenteral nutrition (PN) contamination with peroxides almost doubles, which increases oxidative stress in preterm infants, contributing to the development of bronchopulmonary dysplasia. The American Society for Parenteral and Enteral Nutrition (ASPEN) recommends complete PN photoprotection to reduce peroxide contamination and optimize its integrity but acknowledges the challenges of its implementation. In this study, a novel photoprotection procedure was tested for its effectiveness in reducing peroxide load and limiting ascorbic acid degradation, and for its feasibility and effectiveness in reducing urinary peroxide levels in preterm infants.
View Article and Find Full Text PDFJ Obstet Gynecol Neonatal Nurs
January 2025
Objective: To examine patient-provider nutrition conversations at initial prenatal visits.
Design: Convergent mixed methods observational study.
Setting: Two large metropolitan clinics in the midwestern United States.
Lancet Neurol
February 2025
Janssen Research & Development, a Johnson & Johnson Company, Titusville, NJ, USA.
Background: Given burdensome side-effects and long latency for efficacy with conventional agents, there is a continued need for generalised myasthenia gravis treatments that are safe and provide consistently sustained, long-term disease control. Nipocalimab, a neonatal Fc receptor blocker, was associated with dose-dependent reductions in total IgG and anti-acetylcholine receptor (AChR) antibodies and clinically meaningful improvements in the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale in patients with generalised myasthenia gravis in a phase 2 study. We aimed to assess the safety and efficacy of nipocalimab in a phase 3 study.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!